Bayer
Pharmaceuticals
Germany
EU Taxonomy summary
38.4% of Bayer's revenues are EU Taxonomy eligible, with 0% also being Taxonomy aligned. 16.3% of Bayer's capital expenditures are EU Taxonomy eligible, with 0% also being Taxonomy aligned. Additionally, 2.2% of Bayer's operating expenses are EU Taxonomy eligible, with 0% also being Taxonomy aligned.
Bayer's revenues breakdown
Bayer's capital expenditures breakdown
Bayer's operating expenses breakdown
EU Taxonomy full disclosure
Revenues
FY2023 | Code | Value (EURm) | Proportion of total | CCM | CCA | WTR | PPC | CE | BIO | CCM DNSH | CCA DNSH | WTR DNSH | PPC DNSH | CE DNSH | BIO DNSH | Minimum safeguards | Previous year proportion | Category enabling activity | Category transitional activity | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Turnover of environmentally sustainable activities (Taxonomy-aligned) (A.1) |
0 | 0% | 0% | 0% | 0% | 0% | 0% | 0% | ||||||||||||
Of which enabling |
0 | 0% | 0% | 0% | 0% | 0% | 0% | 0% | ||||||||||||
Of which transitional |
0 | 0% | 0% | |||||||||||||||||
Manufacture of medicinal products |
PPC 1.2 | 18,299 | 38.4% | N/EL | N/EL | N/EL | EL | N/EL | N/EL | |||||||||||
Turnover of Taxonomy-eligible but not environmentally sustainable activities (not Taxonomy-aligned activities) (A.2) |
18,299 | 38.4% | 0% | 0% | 0% | 100% | 0% | 0% | ||||||||||||
A. Turnover of Taxonomy eligible activities (A.1+A.2) |
18,299 | 38.4% | 0% | 0% | 0% | 100% | 0% | 0% | ||||||||||||
Turnover of Taxonomy-non-eligible activities |
29,338 | 61.6% | ||||||||||||||||||
Total (A+B) |
47,637 | 100% |
Capital expenditures
FY2023 | Code | Value (EURm) | Proportion of total | CCM | CCA | WTR | PPC | CE | BIO | CCM DNSH | CCA DNSH | WTR DNSH | PPC DNSH | CE DNSH | BIO DNSH | Minimum safeguards | Previous year proportion | Category enabling activity | Category transitional activity | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CapEx of environmentally sustainable activities (Taxonomy-aligned) (A.1) |
0 | 0% | 0% | 0% | 0% | 0% | 0% | 0% | ||||||||||||
Of which enabling |
0 | 0% | 0% | 0% | 0% | 0% | 0% | 0% | ||||||||||||
Of which transitional |
0 | 0% | 0% | |||||||||||||||||
Construction, extension and operation of waste water collection and treatment |
CCM 5.3 | 0 | 0% | EL | N/EL | N/EL | N/EL | N/EL | N/EL | |||||||||||
Renewal of waste water collection and treatment |
CCM 5.4 | 3 | 0.1% | EL | N/EL | N/EL | N/EL | N/EL | N/EL | |||||||||||
Transport by motorbikes, passenger cars and light commercial vehicles |
CCM 6.5 | 32 | 1% | EL | N/EL | N/EL | N/EL | N/EL | N/EL | |||||||||||
Renovation of existing buildings |
CCM 7.2 | 19 | 0.6% | EL | N/EL | N/EL | N/EL | N/EL | N/EL | |||||||||||
Installation, maintenance and repair of energy efficiency equipment |
CCM 7.3 | 1 | 0% | EL | N/EL | N/EL | N/EL | N/EL | N/EL | |||||||||||
Installation, maintenance and repair of instruments and devices for measuring, regulation and controlling energy performance of buildings |
CCM 7.5 | 0 | 0% | EL | N/EL | N/EL | N/EL | N/EL | N/EL | |||||||||||
Acquisition and ownership of buildings |
CCM 7.7 | 16 | 0.5% | EL | N/EL | N/EL | N/EL | N/EL | N/EL | |||||||||||
Manufacture of medicinal products |
PPC 1.2 | 472 | 14.1% | N/EL | N/EL | N/EL | EL | N/EL | N/EL | |||||||||||
CapEx of Taxonomy-eligible but not environmentally sustainable activities (not Taxonomy-aligned activities) (A.2) |
543 | 16.3% | 13.497% | 0% | 0% | 86.503% | 0% | 0% | ||||||||||||
A. CapEx of Taxonomy eligible activities (A.1+A.2) |
543 | 16.3% | 13.497% | 0% | 0% | 86.503% | 0% | 0% | ||||||||||||
CapEx of Taxonomy-non-eligible activities |
2,798 | 83.7% | ||||||||||||||||||
Total (A+B) |
3,341 | 100% |
Operating expenses
FY2023 | Code | Value (EURm) | Proportion of total | CCM | CCA | WTR | PPC | CE | BIO | CCM DNSH | CCA DNSH | WTR DNSH | PPC DNSH | CE DNSH | BIO DNSH | Minimum safeguards | Previous year proportion | Category enabling activity | Category transitional activity | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OpEx of environmentally sustainable activities (Taxonomy-aligned) (A.1) |
0 | 0% | 0% | 0% | 0% | 0% | 0% | 0% | ||||||||||||
Of which enabling |
0 | 0% | 0% | 0% | 0% | 0% | 0% | 0% | ||||||||||||
Of which transitional |
0 | 0% | 0% | |||||||||||||||||
Manufacture of medicinal products |
PPC 1.2 | 161 | 2.2% | N/EL | N/EL | N/EL | EL | N/EL | N/EL | |||||||||||
OpEx of Taxonomy-eligible but not environmentally sustainable activities (not Taxonomy-aligned activities) (A.2) |
161 | 2.2% | 0% | 0% | 0% | 100% | 0% | 0% | ||||||||||||
A. OpEx of Taxonomy eligible activities (A.1+A.2) |
161 | 2.2% | 0% | 0% | 0% | 100% | 0% | 0% | ||||||||||||
OpEx of Taxonomy-non-eligible activities |
7,043 | 97.8% | ||||||||||||||||||
Total (A+B) |
7,204 | 100% |